Pooled Mutant KRAS-Targeted Long Peptide Vaccine

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer vaccine containing a mixture of synthetic long peptides (SLPs) targeting six KRAS mutations, including KRAS G12D, G12R, G12V, G12A, G12C and G13D, and the adjuvant poly-ICLC, with potential immunostimulatory and antineoplastic activities. Upon administration, pooled mutant KRAS-targeted long peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against KRAS G12D/G12R/G12V/G12A/G12C/G13D-expressing tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - KRAS G12D/G12R/G12V/G12A/G12C/G13D Peptide-Poly-ICLC Vaccine mKRASvax - KRAS Peptide Vaccine - Mutant KRAS Peptide-Hiltonol Vaccine mKRASvax - Mutated KRAS Peptide-Poly-ICLC Vaccine mKRASvax - Pooled Mutant KRAS Peptide Vaccine - SLP mKRASvax - Synthetic Long Peptide Mutant KRAS Vaccine - mKRASvax